体外受精の日本市場の評価：製品別、周期タイプ別、処置別、流通チャネル別、地域別、機会、予測（2018年度～2032年度）

日本の体外受精の市場規模は、2024年度の16億2,000万米ドルから2032年度に26億米ドルに達すると予測され、2025年度～2032年度の予測期間にCAGRで6.10%の成長が見込まれます。市場の成長を後押ししているのは、老年人口の拡大、生殖補助医療（ART）の社会的受容の拡大、出生率の低下、政府による支援的な政策や取り組みの導入、子育てを先延ばしにする志向の高まりなどです。国の医療部門における研究開発への取り組みと先進技術の導入は、体外受精（IVF）の成功率を高め、日本の市場の拡大をさらに後押ししています。

政府は日本の出生率を高めるためにさまざまな対策に取り組んでいます。これらの施策には、卵細胞を凍結保存する女性に対する助成金の支給も含まれます。2025年2月、東京都港区は、将来の妊娠・出産に備えて卵子凍結を行う女性に対し、都の助成金を利用している場合、10万円（約643米ドル）を追加助成すると発表しました。これは東京都の自治体が始めた過去に類を見ない取り組みで、4月から開始されます。不妊症の大きな原因の1つは、加齢とともに低下する卵子の質です。医療機関での採卵・凍結費用は40万円（約2,672米ドル）です。東京都では、卵子凍結を行った18～39歳の女性に20万円（約1,336米ドル）の助成金を支給しています。港区は、約40人の区民がこの助成を受けると見込んでおり、この追加支給によって、卵子凍結を選択する人が増えると予測しています。このような取り組みにより、体外受精を含むさまざまな生殖技術の採用が促進され、市場に有利な成長機会がもたらされると予測されます。

当レポートでは、日本の体外受精市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 日本の体外受精市場の見通し（2018年度～2032年度）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • 製品別
  • 周期タイプ別
  • 処置別
  • 流通チャネル別
  • 地域別
  • 市場シェア分析（上位5社とその他、金額）（2024年度）
• 市場マップ分析（2024年度）
  • 製品別
  • 周期タイプ別
  • 処置別
  • 流通チャネル別
  • 地域別

第5章 需給分析

第6章 バリューチェーン分析

第7章 ポーターのファイブフォース分析

第8章 PESTLE分析

第9章 価格分析

第10章 市場力学

• 市場促進要因
• 市場の課題

第11章 市場の動向と発展

第12章 規制枠組みとイノベーション

• 規制当局の承認

第13章 特許情勢

第14章 ケーススタディ

第15章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • Thermo Fisher Scientific, Inc.
  • Hamilton Thorne, Inc.
  • Cook Medical Inc.
  • Cooper Surgical Inc.
  • Bayer AG
  • Esco Lifesciences Group
  • Genea Pty Limited
  • Kitazato Corporation
  • Eppendorf Japan Ltd.
  • Corning Incorporated

第16章 戦略的提言

第17章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan In-vitro Fertilization Market, By Value, In USD Million, FY2018-FY2032F
• Figure 2. Japan In-vitro Fertilization Market Share (%), By Product, FY2018-FY2032F
• Figure 3. Japan In-vitro Fertilization Market Share (%), By Type of Cycle, FY2018-FY2032F
• Figure 4. Japan In-vitro Fertilization Market Share (%), By Procedure, FY2018-FY2032F
• Figure 5. Japan In-vitro Fertilization Market Share (%), By Distribution Channel, FY2018-FY2032F
• Figure 6. Japan In-vitro Fertilization Market Share (%), By Region, FY2018-FY2032F
• Figure 7. By Product Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 8. By Type of Cycle Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 9. By Procedure Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 10. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 11. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2024

Japan in-vitro fertilization market is projected to witness a CAGR of 6.10% during the forecast period FY2025-FY2032, growing from USD 1.62 billion in FY2024 to USD 2.60 billion in FY2032. The growth of the market is boosted by the expansion of the geriatric population, increasing social acceptance of assisted reproductive technologies (ART), declining birth rate, introduction of supportive government policies and initiatives, and growing preference for delayed parenthood. The country's commitment to research and development in the healthcare sector coupled with the introduction of advanced technologies is bolstering the success rate of in-vitro fertilization (IVF), further supporting the market's expansion in Japan.

The government is working on various measures to boost the birth rate of the country. These measures include provision of subsidy for women for freezing egg cells. In February 2025, Tokyo's Minato Ward announced that it will provide an additional subsidy of approximately USD 643 (100,000 yen) to women that are using the capital's subsidies for freezing their eggs to prepare for future pregnancy and childbirth. This is the first of its kind initiative that was launched by a municipality in Tokyo and is set to be launched in April. One of the major causes of infertility is the quality of eggs, which decline with age. The cost of retrieving and freezing eggs at medical institutions is approximately USD 2,672 (400,000 yen). Tokyo provides a subsidy of about USD 1,336 (200,000 yen) for women who are 18-39 years old and have had their eggs frozen. The Minato Ward estimates that approximately 40 residents will receive the subsidy and predicts that the provision of the additional amount is going to encourage more individuals to opt for freezing of eggs. Such efforts are expected to bolster the adoption of various reproductive technologies including IVFs and provide lucrative growth opportunities for the market.

Technological Advancements Support Market Expansion

Rapid advancements in technology are one of the major factors driving the growth of the Japan in-vitro fertilization market. Innovations including improved embryo culture techniques and preimplantation genetic testing along with advancements in cryopreservation techniques are enhancing the success rate and effectiveness of IVF treatments. This is because these services allow for more precise monitoring of the embryo and provide better conditions for its early development, resulting in increased success rates of the treatments. Additionally, researchers across Japan are also working on developing new technologies and services to improve fertility among women.

For instance, in August 2024, a team of researchers from Shinshu University developed a new technique for egg maturation for improving IVF outcomes. The team of researchers have also discovered a new method for producing viable, embryo-forming eggs from underdeveloped cells. The team created a system that reconstructs the protective cell layer of the eggs that are immature. By demonstrating the potential to produce viable eggs from undeveloped oocytes, the researchers contribute to the development of IVF procedures that are more efficient and effective. Such efforts are driving the growth of the in-vitro fertilization market in Japan by offering new solutions to combat infertility and improve the success rate of existing technologies.

Rising Cases of Infertility Bolster Market's Demand

As more and more couples face challenges with conceiving naturally in Japan, the demand for procedures such as IVFs is significantly increasing. An article published in the Journal of Occupational Health in April 2024 has estimated that 1 in 4.4 couples in Japan are undergoing infertility treatments or testing. Various factors that are boosting the number of cases of infertility in the country include lifestyle changes and growing preference for delayed parenthood. Moreover, evolving societal norms and destigmatization of fertility services in Japan are also propelling the market's growth and expansion.

Increasing Awareness About IVF Boosts Market Expansion

The rising number of awareness campaigns in the country are playing a crucial role in augmenting the market's expansion as they play a significant role in improving public understanding about fertility treatments and eliminating stigma associated with infertility. This is essential due to the rising cases of infertility and decreasing birth rate in Japan. According to various estimates, only 661,577 births were reported in the first eleven month in Japan in 2024. Apart from increasing awareness about IVF services, the government is also working on boosting the accessibility and affordability of the service in order to combat the country's declining birth rate. Thus, providing lucrative growth opportunities for the market.

Frozen Non-donor Accounts for Significant Market Share

The segment accounts for a significant share of the market due to the relatively cost-effective nature of the cycle, which reduces both the potential financial and hormonal burdens associated with other types of cycles. Moreover, the utilization of frozen non-donor biological materials eliminates the requirement for collection of sperm and fresh egg retrieval, making the procedure more convenient for the patients. Additionally, the method is also preferred by a wide range of couples due to its relatively non-complex nature in comparison to other methods. The rising number of first-time couples along with the increased requirement for fertility preservation due to the growing preference for delayed parenthood is also bolstering the popularity of frozen non-donor IVF cycles, positively influencing the expansion of the Japan in-vitro fertilization market.

Future Market Scenario (FY2025 - FY2032F)

According to the Japan in-vitro fertilization market analysis, the market is anticipated to observe significant growth over the forecast period owing to rising cases of infertility, supportive government measures, including favorable regulations and financial incentives to boost population growth, and rapid advancements in reproductive technologies.

The growing popularity of delayed parenthood and marriage in the country to focus on professional growth coupled with increasing awareness and acceptance of ARTs is expected to provide lucrative growth opportunities for the market in the coming years. This societal shift is going to be vital in amplifying the demand for various fertility services including IVFs in Japan.

With continuous advancements in medical technology and an increase in the number of fertility clinics in the country, the success rates and accessibility of IVF is expected to improve in the coming years. These factors combined are anticipated to accelerate the growth of the Japan in-vitro fertilization market.

Key Players Landscape and Outlook

Increasing investments by leading pharmaceutical companies in Japan to bolster the availability of high-quality fertility treatments in the country and enhance treatment outcomes of IVF procedures is propelling the market's expansion. In August 2024, Rohto Pharmaceutical Co., Ltd. joined BAIBYS Fertility Ltd.'s Series A funding round. The latter developed a system that aids medical professionals in examining sperm samples and identifying the specimens that are most ideal according to the criteria set up by the World Health Organization (WHO). The company's automated approach addresses the inefficiencies that occur in traditional methods and ensures the accessibility and affordability of advanced fertility solutions. Thus, providing lucrative growth opportunities for the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan In-vitro Fertilization Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product
    • 4.2.1.1. Equipment
    • 4.2.1.2. Reagents and Culture Media
  • 4.2.2. By Type of Cycle
    • 4.2.2.1. Fresh Donor
    • 4.2.2.2. Frozen Donor
    • 4.2.2.3. Fresh non-donor
    • 4.2.2.4. Frozen non-donor
  • 4.2.3. By Procedure
    • 4.2.3.1. Conventional In-vitro Fertilization
    • 4.2.3.2. In-vitro Fertilization with ICSI
    • 4.2.3.3. In-vitro Fertilization with Donor Eggs
    • 4.2.3.4. Minimal In-vitro Fertilization
    • 4.2.3.5. Others
  • 4.2.4. By Distribution Channel
    • 4.2.4.1. Fertility Clinics
    • 4.2.4.2. Hospitals
    • 4.2.4.3. Surgical Centers
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North [Hokkaido and Tohoku]
    • 4.2.5.2. Central [Kanto and Chubu]
    • 4.2.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Product
  • 4.3.2. By Type of Cycle
  • 4.3.3. By Procedure
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Market Trends and Developments

12. Regulatory Framework and Innovation

• 12.1. Regulatory Approvals

13. Patent Landscape

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. Thermo Fisher Scientific, Inc.
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. Hamilton Thorne, Inc.
  • 15.3.3. Cook Medical Inc.
  • 15.3.4. Cooper Surgical Inc.
  • 15.3.5. Bayer AG
  • 15.3.6. Esco Lifesciences Group
  • 15.3.7. Genea Pty Limited
  • 15.3.8. Kitazato Corporation
  • 15.3.9. Eppendorf Japan Ltd.
  • 15.3.10. Corning Incorporated

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer